Boehringer Ingelheim reports positive Trajenta data in specific populations

Boehringer Ingelheim and Lilly have reported positive data that demonstrates the positive benefits their diabetes drug Trajenta can provide for vulnerable patient populations.

Results shared at the Asian Association for the Study of Diabetes annual meeting shows that Trajenta offers strong efficacy and tolerability in people with type 2 diabetes and liver disease, as well as Asian diabetes sufferers aged 65 years or older.

Both of these groups generally experience complications that limit their choice of treatment for diabetes, making the development of safe new therapy options particularly important.

Professor Klaus Dugi, corporate senior vice-president for medicine at Boehringer Ingelheim, said: "The findings that will be presented at AASD support linagliptin's safety and efficacy in these populations with type 2 diabetes and confirm that linagliptin is an important treatment option."

The therapy has received approval in a number of diabetes indications in the US, Europe, Japan and other territories.

This comes after Boehringer Ingelheim also recently reported positive trial data for faldaprevir, its new therapy for genotype-1 hepatitis C infections.